A review of gliptins for 2014: Expert Opinion on.
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text.Linagliptin belongs to a group of medicines called dipeptidylpeptidase-4 inhibitors (DPP-4 inhibitors) or gliptins. It's used to treat type 2 diabetes, which is caused by problems with a hormone in your body called insulin. Gliptins help your body make more insulin. They also stop your body releasing too much sugar (glucose) into your blood.Gliptins improve glycaemic control in type 2 diabetes Sitagliptin (Januvia), vildagliptin (Galvus) and saxagliptin (Onglyza) are dipeptidyl peptidase-4 (DPP-4) inhibitors. They improve glycaemic control in diabetes that has not been adequately controlled with metformin or sulfonylurea. Gliptins are PBS listed for add-on combination therapy.
Let’s recap on gliptin DPP-4 inhibitors. The Pharmaceutical Journal 1 MAY 2013 By Carina Livingstone. Carina Livingstone Corresponding Author. Pharmacist, Duncan Livingstone. Duncan Livingstone Corresponding Author. Pharmacist. There are currently four agents that inhibit dipeptidylpeptidase-4 available in the UK. Commonly called “gliptins”, they are a relatively new class of drugs.The issue related to macrovascular outcomes and intensive glycemic control was hotly debated after the publication of landmark trials like ACCORD, ADVANCE, and VADT. The only benefits seem to come from intervening early on in the disease process as indicated by the 10-year UKPDS follow-up. To complicate matters USFDA made it mandatory for modern drugs to conduct cardiovascular safety trials in.
Sitagliptin and vildagliptin are dipeptidyl peptidase-4 (DPP-4) inhibitors ('gliptins'). They provide similar improvements in glycaemic control for people with type 2 diabetes mellitus. The effect of gliptins on diabetes-related complications and mortality is unknown.
